Mylan is facing a torrent of scrutiny from lawmakers who are up in arms over the company’s decision to raise the price of the EpiPen, which contains a lifesaving drug for people with severe allergies.

The company has been asked to send representatives to Capitol Hill to explain the price increase to the House Oversight Committee. Other members of Congress have also made inquiries about the drug.

ADVERTISEMENT

Mylan has raised the cost of an EpiPen two-pack to $608, up from the around $100 the product cost when the company acquired the patent from Merck in2007.

Reps. Jason Chaffetz Jason ChaffetzThe myth of the conservative bestseller Elijah Cummings, Democratic chairman and powerful Trump critic, dies at 68 House Oversight panel demands DeVos turn over personal email records MORE (R-Utah) and Elijah Cummings (D-Md.), the top Republican and Democrat on the House Oversight Committee, on Tuesdaysent a letter to the company’s CEO, Heather Bresch, seeking a non-public briefing by Sept. 6.

“I would believe, knowing these committees, that [lawmakers] want them to come in, share information with them and then blast them at a committee hearing,” said a person with knowledge of congressional investigations who asked for anonymity to speak freely.

Although no hearings on the EpiPen have been scheduled in the House or the Senate, dozens of members have called for a closer look at the company.

Sens. Chuck Grassley Charles (Chuck) Ernest GrassleyGardner signals support for taking up Supreme Court nominee this year Grassley, Ernst pledge to 'evaluate' Trump's Supreme Court nominee McConnell digs in on vow to fill Ginsburg's Supreme Court seat MORE (R-Iowa) and Bernie Sanders Bernie SandersJacobin editor: Primarying Schumer would force him to fight Trump's SCOTUS nominee Trump campaign plays up Biden's skills ahead of Cleveland debate: 'He's actually quite good' Young voters backing Biden by 2:1 margin: poll MORE (I-Vt.), have said the company’s plans to release a generic version of the drug and offer coupons to offset the cost of EpiPens are not enough.

“You always ask them to come in first and provide information,” said the congressional investigation expert. “The committee has to understand the process before they have a hearing. Believe me, they will have hearings on this one.”

The Oversight panel requested a raft of documents that detail profits and expenses related to manufacturing of the EpiPen, in addition to information on research and development and marketing. They also asked the company to provide its state and federal lobbying disclosure forms from 2007 to 2016, among other things.

Companies that are facing such investigations from Congress typically hire lobbying firms to help them navigate the process.

A Mylan spokeswoman declined to comment on the company’s lobbying.

Disclosure records show that Mylan as spent more than $11 million to advocate before the federal government since 2007, when it purchased the EpiPen patent.

The company announced this week that it would be releasing a generic of the EpiPen — which will cost $300 per two-pack — and giving some consumers $300 savings coupons, if they are paying out-of-pocket for the brand-name version.

Mylan, whose CEO is the daughter of Sen. Joe Manchin Joseph (Joe) ManchinTrump meets with potential Supreme Court pick Amy Coney Barrett at White House Names to watch as Trump picks Ginsburg replacement on Supreme Court Momentum growing among Republicans for Supreme Court vote before Election Day MORE (D-W.Va.), employs three in-house lobbyists who handle policy issues for the company.

The company lobbied successfully to pass legislation that encourages schools to keep EpiPens on hand. Congress passed the School Access to Emergency Epinephrine Act in 2013.

Mylan also employs outside firms: the Evertz Group and West Front Strategies.

In lobbying disclosure forms, Evertz Group reported working primarily on HIV/AIDS-related issues for Mylan, including the “promotion of federal legislation related to reimbursement for provision of care for those living with HIV/AIDS.” Mylan has a portfolio of antiretroviral drugs to treat patients with HIV/AIDS.

West Front Strategies, which began working for Mylan last year, appears to have a wider policy portfolio — lobbying on appropriations bills, corporate tax reform initiatives, intellectual property provisions in trade deals, proposed regulations at the Food and Drug Administration (FDA), patent reform, 21st Century Cures legislation, generic drug pricing policy and Medicare reimbursement issues.

The firm declined to talk about its work for Mylan and whether it was increasing its outreach to Capitol Hill because of the EpiPen controversy.

Lobbyists at the firm have experience working for Senate Majority Leader Mitch McConnell Addison (Mitch) Mitchell McConnellGraham: GOP will confirm Trump's Supreme Court nominee before the election Trump puts Supreme Court fight at center of Ohio rally The Memo: Dems face balancing act on SCOTUS fight MORE (R-Ky.), House Republican leadership, Sen. Ron Kind Ronald (Ron) James KindWisconsin Rep. Ron Kind wins primary Democrats exit briefing saying they fear elections under foreign threat Bottom line MORE (D-Wis.) and the George W. Bush Administration.

Both Mylan’s in-house lobbying force and West Front Strategies have encouraged lawmakers to consider that epinephrine auto-injectors be required on airplanes, according to disclosure forms.

Sens. Mark Kirk Mark Steven KirkLiberal veterans group urges Biden to name Duckworth VP On the Trail: Senate GOP hopefuls tie themselves to Trump Biden campaign releases video to explain 'what really happened in Ukraine' MORE (R-Ill.) and Jeanne Shaheen Cynthia (Jeanne) Jeanne ShaheenSenate Democrats introduce bill to sanction Russians over Taliban bounties Trump-backed candidate wins NH GOP Senate primary to take on Shaheen Democratic senator urges Trump to respond to Russian aggression MORE (D-N.H.) introduced the Airline Access to Emergency Epinephrine Act last year. Lobbyists for Mylan pushed unsuccessfully to have the bill added to the Federal Aviation Administration’s (FAA) reauthorization measure.

While the EpiPens for plane provision was in the Senate version of the bill, it did not make it into the final law.

The pharmaceutical industry has a robust lobbying presence in Washington, with more than 100 companies and trade groups spending upwards of $148 million to lobby the federal government last year, according to data from the Center for Responsive Politics.

Among drug companies, Mylan ranks below the top spenders on lobbying, though it still devotes more than $1 million per year to lobbying. Last year, it spent $1.55 million.

Mylan’s larger competitors — Amgen, Pfizer and Bayer — each spent between $7.6 million and $10.5 million on lobbying in 2015.

There are also lobbying groups in Washington that fight to bring down drug prices, including a relatively new player, The Campaign for Sustainable Rx Pricing (CSRxP).

Rodney Whitlock, a policy advisor for the organization, told The Hill that his group plans to make Mylan a poster child for unnecessary price hikes. It is “a drug that has been on the marketplace for a long time, and is undergoing significant price increases over time greater than the pace of inflation,” he said.

“This will move to front and center of the examples we give,” he said.

On Monday, several public interest groups sent a letter to Mylan, demanding that it do more to make the EpiPen for consumers, most of whom depend on the lifesaving device.

Public Citizen, MoveOn.org Civic Action, The Other 98%, Social Security Works, MomsRising, Democracy for America, Sum of Us, Sierra Rise, Doctors for America, and Consumers Union collected more than 700,000 signatures for a petition accompanying the letter.

The release of a generic epinephrine auto-injector “is just one more convoluted mechanism for Mylan executives to avoid plain talk, admit their price gouging and just cut the price of EpiPen,” said Robert Weissman, the president of Public Citizen, in a statement.

“They should be ashamed of themselves. But even if they are not, they should recognize that the issue is not going away until the company rolls back the EpiPen price,” he said.